SCHEMBL3208113

SCHEMBL3208113

COCCOc1ccc(CC=O)c(OCc2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC8 Q9BY41 1/20 0.41
MAOB P27338 2/20 0.41
MAOA P21397 1/20 0.41
ABCB1 P08183 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTR1A P08908 3/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
PPARA Q07869 1/20 0.40
ALOX5 P09917 1/20 0.39
MET P08581 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3959610 0.88 MAOB (0.51) LMNAMAOBMAOAALOX5
SCHEMBL6887763 0.87 HDAC8 (0.53) KDM4ENPC1HDAC8MAOBABCB1
SCHEMBL3211263 0.82 HDAC8 (0.51) KDM4EMEN1NPC1LMNAKMT2A
SCHEMBL3206472 0.81 ABCB1 (0.47) KDM4EMEN1NPC1LMNAKMT2A
SCHEMBL3211308 0.81 CYP4F2 (0.49) KDM4EMEN1NPC1LMNAKMT2A
SCHEMBL3217103 0.79 LTA4H (0.50) KDM4EMEN1NPC1LMNAKMT2A
SCHEMBL6885785 0.79 PTGER1 (0.49) NPC1LMNAMAOBMAOAL3MBTL1
SCHEMBL23000105 0.78 KDM4E (0.42) KDM4EMEN1NPC1LMNAKMT2A
SCHEMBL12502531 0.78 MAOB (0.45) NPC1LMNAMAOBMAOAALOX5
SCHEMBL19068931 0.77 MAOB (0.51) KDM4EMEN1NPC1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
CN-101282725-A Therapeutic agent for diabetes TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2008-10-08 CN disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 KDM4E 1872/4885MEN1 3927/4885NPC1 1683/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 KDM4E 2362/4885MEN1 3517/4885NPC1 1377/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 KDM4E 1872/4885MEN1 3927/4885NPC1 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.